Newsbenzinga
Pfizer Expands Breast Cancer Drug Reach with New FDA Nod for Metastatic Disease
· Published
Article summary
The FDA approved Pfizer's TUKYSA combination as a front-line maintenance therapy for advanced HER2-positive breast cancer.
An excerpt from the original article.
Comments —
Loading comments…